PDL BioPharma EBITDA 2010-2020 | PDLI

PDL BioPharma ebitda from 2010 to 2020. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
PDL BioPharma Annual EBITDA
(Millions of US $)
2020 $
2019 $-82
2018 $-23
2017 $232
2016 $151
2015 $563
2014 $565
2013 $439
2012 $370
2011 $355
2010 $220
2009 $302
PDL BioPharma Quarterly EBITDA
(Millions of US $)
2020-12-31
2020-06-30 $-13
2020-03-31 $-31
2019-12-31 $-88
2019-09-30 $17
2019-06-30 $-6
2019-03-31 $-5
2018-12-31 $38
2018-09-30 $41
2018-06-30 $-116
2018-03-31 $14
2017-12-31 $40
2017-09-30 $43
2017-06-30 $122
2017-03-31 $27
2016-12-31 $2
2016-09-30 $41
2016-06-30 $13
2016-03-31 $96
2015-12-31 $165
2015-09-30 $119
2015-06-30 $134
2015-03-31 $146
2014-12-31 $105
2014-09-30 $163
2014-06-30 $161
2014-03-31 $137
2013-12-31 $111
2013-09-30 $95
2013-06-30 $145
2013-03-31 $88
2012-12-31 $88
2012-09-30 $83
2012-06-30 $125
2012-03-31 $74
2011-12-31 $71
2011-09-30 $83
2011-06-30 $121
2011-03-31 $80
2010-12-31 $-26
2010-09-30 $78
2010-06-30 $114
2010-03-31 $55
2009-12-31 $55
2009-09-30 $67
2009-06-30 $121
2009-03-31 $59
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00